TLC - InspirMed's inhalable liposome formulations shows encouraging action in COVID-19

InspirMed, a subsidiary of Taiwan Liposome (TLC) presents findings from two separate studies in rats on ISPM21 and ISPM19, respectively, as well as from a ISPM19 lung deposition study at the 23rd International Society for Aerosols in Medicine ((ISAM)) Congress.Pharmacokinetic studies on inhalable liposomal GS-441524 (ISPM21) and inhalable liposomal hydroxychloroquine (ISPM19) showed significantly higher concentrations in the lungs than their conventional counterparts, giving ISPM21 and ISPM19 potential as prophylaxis and/or treatment for COVID-19. Intratracheally administered ISPM21 had a long half-life of 22.8 hours, with significantly higher concentrations (>200-fold) in the lung and comparable systemic exposure in the plasma compared to an equal dose of intravenously administered GS-441524 solution.Intratracheally administered ISPM19 had a longer half-life (~2.5-fold) and higher exposure in the lung (~30-fold) than intravenously administered free hydroxychloroquine.ISPM19 nebulized into an aerosol exhibited a lung deposition rate (inhaled dose) of 26.67%.InspirMed’s inhalable liposome formulation programs can deliver antiviral drugs directly into the lung

For further details see:

InspirMed's inhalable liposome formulations shows encouraging action in COVID-19